Business Context and Reporting Period
NextCure, Inc., a Delaware corporation, filed this Form 8-K on December 2, 2019, to report the full exercise of an underwriters' option in its recent public offering of common stock. The company is listed on the Nasdaq Global Select Market under the symbol NXTC and is classified as an emerging growth company.
Key Financial Metrics
- Option Exercise Proceeds: Approximately $22.5 million in gross proceeds from the purchase of 611,578 additional shares.
- Offering Price: $36.75 per share.
- Total Gross Proceeds: Approximately $172.3 million from the entire offering (original closing plus option exercise).
- Net Proceeds: The filing does not provide a clear value for net proceeds after deducting underwriting discounts, commissions, and offering expenses.
- Revenue, Profit, and Cash Flow: The filing does not provide a clear value for these operational metrics as this is a transaction-specific report.
Material Changes
The primary material change is the increase in total capital raised from the public offering. The original offering closed on November 19, 2019, and the option exercise closed on December 2, 2019, increasing the total gross proceeds to approximately $172.3 million.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding future guidance, outlook, or specific risks beyond the standard disclosure of the transaction. No unusual items or contingencies were disclosed in this report.
Investor Verification Checklist
- Verify the final net proceeds after deducting underwriting discounts and offering expenses.
- Confirm the updated total share count and dilution impact following the issuance of 611,578 additional shares.
- Review the company's use of proceeds for the $172.3 million raised.